Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

2 TO OUR SHAREHOLDERS In fiscal 2000, which ended March 31, 2001, Eisai achieved record consolidated results, due to the continued sales growth in global markets of the Alzheimer’s disease treatment Aricept, and the proton pump inhibitor Aciphex/Pariet. This achievement reflects the ongoing support of shareholders and other stakeholders in the Company. On behalf of everyone at Eisai, we would like to express our sincerest appreciation. Eisai sees our ultimate goal as satisfying customers—the patients using our products—and our fundamental mission as determining effective ways and allocating management resources effectively to achieve this goal. Accordingly, we focus on developing pharmaceuticals that satisfy unmet medical needs and enhance the quality of life of patients worldwide. We also observe the highest standards of quality and aim to provide information in easily accessible formats. With Aricept, we have established a safe and effective course of treatment for Alzheimer’s disease. Aricept has received approval in 78 countries and is playing a crucial role in efforts to treat patients with mild to moderate Alzheimer's disease. We are also developing an agent for treating sepsis, E5564, which is produced using proprietary synthesis technologies. In the area of cancer research, we are pursuing the development of substances with various mechanisms—such as E7070 that affects the cell cycle at the G1 stage, tubulin antagonists and antiangiogenics, which inhibit blood vessel formation—that offer new hope for treating this disease. In the field of neurology, which we have positioned as our most important strategic therapeutic area, we are working toward the development of effective treatments for neurogenerative disorders including multiple sclerosis and other illnesses. Substances currently in development include the serotonin receptor antagonist E2101, and the amino-3-hydroxy-5-methyl-4isoxazolepropionate (AMPA) type glutamate receptor antagonist E2007, for which we have received a concept patent for the inhibition of neural dysfunction associated with multiple selerosis. Our research in the neurology area also includes the development of additional indications for Aricept. Eisai Annual Report 2001
In Japan, we are proceeding with development of the antirheumatic agents, T-614 and D2E7, the latter of which is a genetically engineered tumor necrosis factor (TNF-α) antagonist, and the obesity management compound sibutramine. Finally, we are aggressively developing new applications and formulations for Aricept and Aciphex/Pariet, which has already gained approval in 74 countries, to maximize the potential of these groundbreaking drugs. A crucial ongoing task for Eisai is to cultivate a solid technological foundation to support the efforts of our high quality research. Accordingly, we are taking decisive steps, including cooperating with leading external organizations, to maximize cutting-edge genomic technologies. Eisai takes seriously its responsibilities as a manufacturer of prescription pharmaceuticals. Our plants operate in accordance with a stringent quality management system developed to comply with Good Manufacturing Practices (GMP) standards. Our approach to quality and safety focuses on ensuring the patient's peace of mind and is comprehensive, even extending to the use of suitable packaging made with easily disposable, environmentally friendly materials and including appropriate product information. Our approach to marketing places emphasis on raising customer satisfaction through active communication with the medical community. Underscoring the importance of this concept, we have introduced an evaluation system in Japan for medical sales representatives that also assesses contributions to improving customer satisfaction. We will continue to refine this system to facilitate its use both in the formulation and evaluation of overall marketing strategies for medical sales representatives. The pharmaceutical industry faces a host of new issues in the 21st century. A particularly crucial issue is the availability and access to advanced pharmaceuticals by society. We also recognize the importance of establishing solid relationships with customers, shareholders, employees, the community and other individuals and groups interested in or affected by our operations, and we constantly seek Eisai Annual Report 2001 3
Page 1 and 2: Human Health Care The script for ou
Page 3: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11 and 12: Selected Research Candidates (As of
Page 13 and 14: working together to develop antican
Page 15 and 16: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 17 and 18: Consumer Health Care Products The c
Page 19 and 20: REINFORCING OUR RELATIONSHIP WITH S
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

Create successful ePaper yourself

Delete template?

Save as template?